These markers are clear improvement over PSA since they allow a better distinction between benign and malignant prostate gland hypertrophy and improve the prediction of high-grade and clinically aggressive prostatic tumours, especially in cases where PSA levels are in the grey zone [33,34,35,36,37,38]. The gene discussed is PROS1; the disease is prostate neoplasm.